Shares of Olympus Co. (OTCMKTS:OCPNY – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $18.00 and traded as low as $18.00. Olympus shares last traded at $18.00, with a volume of 400 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group raised shares of Olympus to a “buy” rating in a research report on Monday, May 18th. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy”.
View Our Latest Stock Analysis on Olympus
Olympus Price Performance
About Olympus
Olympus Corporation is a Tokyo-headquartered manufacturer specializing in medical and scientific imaging, precision optics and related equipment. The company’s medical systems business is focused on endoscopic technologies and therapeutic devices used in minimally invasive diagnosis and treatment, supplying hospitals and clinical facilities with endoscopes, visualization platforms and accessories. In addition to healthcare, Olympus serves scientific and industrial customers with microscopes, imaging systems, non-destructive testing equipment and precision measurement tools used in research, manufacturing and quality control.
In recent years the company completed a strategic refocus on healthcare and scientific solutions, divesting its consumer camera business in 2020 to concentrate resources on medical device development, services and life-science applications.
Further Reading
- Five stocks we like better than Olympus
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
